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Purpose: Recently, the effect of phosphodiesterase inhibitors (PDE5i) in the lower urinary 
tract symptoms (LUTS) associated to benign prostatic hyperplasia have been studied tho-
roughly.  However, it remains unclear how the PDE5i improve LUTS. Therefore, the aim 
of the present study was to evaluate the potential of acute administration of the PDE5i 
sildenafil to improve detrusor overactivity (DO) induced by Nω-nitro-L-arginine methyl ester 
hydrochloride (L-NAME), an nitric oxide sinthase (NOS) inhibitor, in rats.
Materials and Methods: Twenty-seven MALE adult Wistar Rats were divided into the follo-
wing groups: (1) control, (2) L-NAME, (3) sildenafil alone, and (4) L-NAME + sildenafil.
The NOS blocker L-NAME (20 mg/rat/day) was given in the drinking water. Sildenafil 
(100μg/kg) was administrated intravenously (i.v.) acutely, diluted in cremophor, propylene 
glycol and water. All animals underwent to anesthetized cystometograms.
Results: The chronic and systemic administration of L-NAME markedly increased the num-
ber of non voiding contractions (2.62 (± 0.89)), and frequency of micturition (1.97 (± 0.78)), 
as well increased volume threshold (2.83 mL (± 1.64)) compared with control group, the 
number of non voiding contractions (1.17 (± 0.75)), frequency of micturition (1.08 (± 0.65)) 
and volume threshold (1.16 mL (± 0.38)), p < 0.001, p = 0.01, and p = 0.04, respectively.
Sildenafil infusion decreased the number of micturition cycles significantly from the ba-
seline to end point (-0.93 (± 0.34)) in nitric oxide (NO) deficient animals compared with 
sildenafil infusion alone (control) in animals with normal NO level (0.13 (± 0.25)), p = 0.03.
Conclusion: Systemic reduction of nitric oxide causes detrusor overactivity and acute in-
fusion of sildenafil reduces the number of micturition cycles in chronic NO-deficient rats.
INtRODUctION
Initially, the rationale for the use of phos-
phodiesterase inhibitors (PDE5i) in the treatment 
of lower urinary tract symptoms (LUTS) was ba-
sed on demographic data showing the frequent 
occurrence of both erectile dysfunction (ED) and 
LUTS in men as they age (1,2). Overall, these pre-
liminary data provide experimental support for 
the clinical investigation of PDE5i in the treat-
ment of benign prostatic enlargement (BPE)/
LUTS. After the first clinical study reported im-
provement of LUTS with sildenafil administration 
for men with DE and BPE in 2002 (2), it has been 
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observed a special interest in the role of PDE5i for 
the treatment of LUTS. Although nowadays there 
are several studies of high level of evidence su-
pporting the use of PDE5i in LUTS, the mode of 
action of PDE5i is not yet fully understood.
 Sildenafil, an oral PDE5i, is the most com-
monly prescribed medication for treating ED. By 
inhibiting the degradation of phosphodiesterase 
type-5, vascular smooth muscle relaxation is aug-
mented, thus improving corpora cavernosa blood 
flow. Phosphodiesterase type-5 has been found 
throughout the urinary tract, including the corpus 
cavernosum, clitoris, tunica albuginea, bladder, 
urethra, prostate, ureter and vagina (3).
 The nitric oxide synthase (NOS) inhibitor 
Nω-nitro-L-arginine methyl ester hydrochloride (L-
-NAME) causes significant increase in number of 
non voiding contractions (NVC) micturition cycles 
(MC) in rats. The increase in NVC and MC in expe-
rimental study has been associated with detrusor 
overactivity (DO) (4). In addition, the inhibition 
of arginases, which degrade L-arginine into L-
-ornithine, decreased neurogenic DO in chronic 
spinal cord-injured (SCI) rats (5). Recently, it was 
also showed that 4-week treatment with the NOS 
blocker L-NAME causes in vitro detrusor smooth 
muscle (DSM) supersensitivity to muscarinic ago-
nists via increased levels of [H3]-inositol-phophate, 
accompanied by reductions of β3-adrenoreceptor 
mediated DSM relaxations (6).
Therefore, the aim of the present study was 
to evaluate the potential of acute administration 
of sildenafil to improve DO induced by an NOS 
inhibitor L-NAME in rats.
MAtERIAlS AND MEtHODS
Animals
The experimental protocols were appro-
ved by the Ethical Principles in Animal Resear-
ch adopted by the Brazilian College for Animal 




Animals were randomized into four expe-
rimental groups, as follows:
G1: rats (n=6): control group: the rats re-
ceived drinking water ad libitum
G2: rats (n=6): received L-NAME (20mg/
rat/day) in drinking water for 4 weeks
G3: rats (n=4): received sildenafil (100μg/
Kg) (i.v.) in a single injection.
G4: rats (n=6): received L-NAME(20mg/
rat/day) in drinking water for 4 weeks + sildenafil 
(100μg/Kg) (i.v.) in a single injection.
The volume of water drunk by each rat was 
approximately 50 mL/rat/day. Doses of L-NAME 
and sildenafil were chosen according to our pre-
vious studies (7).
Cystometry in Anesthetized Rats
 Rats were anesthetized with an intrape-
ritoneal injection of urethane (1.2g/kg), and the 
carotid artery cannulated for mean arterial blood 
pressure (MABP) monitoring. A 1-cm incision was 
made along the midline of the rat abdomen. The 
bladder was exposed and a butterfly needle (19G) 
was inserted into the bladder dome and connected 
to a pressure transducer and to an infusion pump. 
Before starting the cystometry, the bladder was 
emptied. Continuous cystometry (CMGs) was car-
ried out by infusing saline into the rat bladder at 
a rate of 4 mL/hr. The following parameters were 
assessed: number of non-voiding contraction 
(NVCs), threshold pressure (TP) mmHg - at which 
micturition began, the peak pressure (PP) mmHg 
- during micturition, volume threshold (VT) mL - 
that was calculated by the time needed for the first 
micturition X 4 mL/60min., micturition cycle (MC) 
calculated as number of cycles per minute and ba-
sal vesical pressure (BP). NVCs were considered 
as spontaneous bladder contractions > 4 mmHg 
from the baseline pressure that did not result in a 
void. The urodynamic variables evaluated and the 
methodology used in the cystometry match those 
described in the literature (8).
Statistics
 Data are expressed as mean ± SD of n ex-
periments. Statistical significance of the differen-
ces was studied by analysis of variance (ANOVA) 
and posteriorly by Bonferroni method. P < 0.05 
was accepted as significant. The software Gra-
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phPad Prism® version 5.00 for Windows® (Gra-
phPad Software, San Diego, California, USA, 2007) 
was used for the statistical analysis.
Drugs
 Nω-nitro-L-arginine methyl ester hydro-
chloride and urethane were obtained from Sigma 
Chem. Co. (St Louis, MO) and Sildenafil from Bio-
lab (SP, Brazil).
RESUltS
The chronic and systemic administration 
of L-NAME (G2) resulted in a significant incre-
ase in total number of non voiding contractions 
(2.62 (± 0.89)) compared with control (G1) (1.17 (± 
0.75)) (p < 0.001; Figure-1). Volume threshold was 
also significantly increased in L-NAME-treated 
rats (G2) (2.83 mL (± 1.64)) when compared with 
control (G1) (1.16 mL (± 0.38)) (p = 0.01; Figu-
re-2). No significant difference was observed in 
the threshold pressure, peak pressure and basal 
bladder pressure comparing L-NAME group with 
control (Table-1).
The number per minute of micturition 
cycles significantly increased in L-NAME-treated 
groups (G2 and G4) when compared with control 
(G1) or sildenafil groups (G3) (P = 0.04; Figure-3). 
Sildenafil infusion to chronically L-NAME treated 
rats (G4) decreased the number of MC significan-
tly from the baseline to end point (-0.93 (± 0.34)) 
compared with sildenafil infusion alone (G3) (0.13 
(± 0.25)), p = 0.03 (Figure-4; Table-2).
The mean time for the response after silde-
nafil infusion was 21.58 (± 13.18) minutes.
L-NAME (G1) administration increased sig-
nificantly the systemic blood pressure (BP) (200.3 
(± 6.77)) mmHg compared with control (G2) (116.9 
(± 3.35) mmHg) (p < 0.05). Comparing the base-
line BP (before sildenafil) with endpoint BP (after 
sildenafil infusion) in the G4 group, it was not 
observed significant change in the arterial blood 
pressure (Figure-5).
DIScUSSION
 In the present study, a chronic deficiency 
of NO was induced by L-NAME. The animals un-
Figure 1 - Number of non-void contractions (NVc) in NO-deficient animals (G2 and G4) compared with controls (G1 and G3). 
Analysis of variance (ANOVA) between groups (p < 0.001). G1 = control, G2 = l-NAME, G3 = Sildenafil alone, and (G4 = l-
-NAME + Sildenafil.
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Figure 2 - Increase in volume threshold (Vt) in NO-deficient animals (G2 and G4) compared with controls (G1 and G3). Analysis of 
variance (ANOVA) between groups (p = 0.01). G1 = control, G2 = l-NAME, G3 = Sildenafil alone, and (G4 = l-NAME + Sildenafil.
table 1 - Administration of Nω-nitro-l-arginine methyl ester hydrochloride (l-NAME) to G1 and G4 rats resulted in increased 
number of non voiding contractions, volume threshold, and micturition cycles compared to the animals with normal level of nitric 
oxide at end point and before sildenafil infusion (G2 and G3, respectively).
Variables Group 1
(n = 6)
Mean / ± SD
Group 2 
(n = 6)
Mean / ± SD
Group 3 
(n = 4)
Mean / ± SD
Group 4
(n = 6)
Mean / ± SD
P
NVC 1.17 / ± 0.75 2.62 / ± 0.89† 0.82 / ± 0.30 1.56 / ± 0.74‡ < 0.001
VT 1.16 / ± 0.38 2.83 / ± 1.64† 1.03 / ± 0.54 1.09 / ± 0.78‡ 0.011
PT 19.14 / ± 3.02 19.13 / ± 2.90 21.63 / ± 4.50 28.16 / ± 11.39 0.06
PP 21.14 / ± 3.06 20.05 / ± 2.93 23.15 / ± 4.77 30.33 / ± 11.12 0.497
MC 1.08 / ± 0.65 1.97 / ± 0.78† 1.27 / ± 0.37 1.38 / ± 0.17‡ 0.04
BP 11.69 / ± 6.77 13.73 / ± 3.35 16.50 / ± 3.11 21.00 / ± 14.08 0.21
G1 = Control, G2 = L-NAME, G3 = Sildenafil alone, and G4 = L-NAME+Sildenafil
NVc - non-voiding contraction, tP - threshold pressure, PP - peak pressure, Vt - volume threshold, Mc - micturition cycled and BP - basal 
pressure. SD - standard deviation, ANOVA - analysis of variance.
The symbols †(P < 0.05) and ‡(P < 0.05) denote statistically significant differences in relation to G1 and G3, respectively (Tukey's multiple 
comparison test).
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Figure 3 - Increase in number of micturition cycle (Mc) in NO-deficient animals (G2 and G4) compared with controls (G1 and 
G3). Analysis of variance (ANOVA) between groups (p < 0.05). G1 = control, G2 = l-NAME, G3 = Sildenafil alone, and (G4 = 
l-NAME + Sildenafil.
Figure 4 - Representative traces showing no change in the amplitude (mmHg) and number of micturition cycles (Mc) after 
sildenafil infusion in a animal of G3 (A), and decrease in amplitude and number of Mc after sildenafil infusion in a rat of G4 
(B). the y-axis scale was stadardized to 5 mmHg and the x-axis for intervals of 4 minutes.
G3 = Single sildenafil injection
G4 = Chronic administration of L-NAME + single sindenafil injection
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derwent CMG and it was observed signifi cant incre-
ase in NVC and VT in rats.
 Therefore, a higher volume threshold be-
comes necessary to initiate micturition. There are 
two theories that could explain this observation: 
increased urethral resistance or detrusor impair-
ment. However, as micturition of the L-NAME rats 
had detrusor pressure similar to control, it suggests 
an increased urethral resistance. This hypothesis is 
corroborated by in vitro pharmacological studies, 
which report that nitric oxide provides relaxation 
of the urethral smooth muscles (9,10). These results 
table 2 - change of number and amplitude of micturition cycles from baseline (before sildenafi l) to end point (after sildenafi l).
G3 G4
Variable N Mean SD P Variable N Mean SD P
DIF MC (mmHg) 4 0.13 0.25 0.875 DIF MC (mmHg) 6 -0.93 0.34 0.031
DIF AMPLIT (mmHg) 4 -0.50 1.71 0.999 DIF AMPLIT 
(mmHg)
6 -17.50 11.72 0.031
G3 = sildenafi l and G4 = L-NAME + sildenafi l
DIF Mc = Difference (Delta) of micturition cycles
DIF AMPlIt = Difference (Delta) of amplitude
SD = Standard Deviation
P refer to comparison from baseline to end point for each group
Figure 5 - Representative traces showing no signifi cative change in the BP (mmHg) after sildenafi l in a NO-defi cient animal 
(G4). It was also observed decrease in amplitude and number of Mc after sildenafi l infusion in the same animal.
BP = Blood pressure
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suggest that NO has an inhibitory effect in muscular 
relaxation both in the bladder and in the urethra of 
animals with chronic deficiency of NO. As demons-
trated in a previous experimental study, the syste-
mic reduction of NO causes detrusor overactivity 
with a decrease in the functional relaxation of the 
urethra (4,6).
 Chronic L-NAME treatment also increased 
the number of micturition cycles in comparison 
with control animals. In this study, acute adminis-
tration of sildenafil during the voiding phase de-
creased amplitude and number of micturition cycles 
in the rats with chronic deficiency of NO; however, 
it did not alter these variables in the control group 
(G3), with normal NO level.
 The exact mechanism through which phos-
phodiesterase inhibitors alleviate BPE/LUTS re-
mains unclear (11). Also, the pathophysiological 
relationship between ED and LUTS is not clear yet, 
but there are several theories to explain it. The can-
didate mechanisms include pelvic atherosclerosis, 
autonomic hyperactivity, the calcium-independent 
Rho-kinase activation pathway and reduced NO le-
vels. It is likely that there is an overlap between the 
roles of each of these candidate mechanisms, and an 
ultimate effect leading to smooth muscle relaxation 
in prostatic, bladder neck, or erectile tissues appears 
to be crucial. Probably the hypothesis of the reduc-
tion of NO is the best explanation.
 Increased smooth muscle tension plays a 
central role in LUTS pathophysiology. The NO/cyclic 
guanosine monophosphate (cGMP) pathway is one 
of the major regulators of smooth muscle contracti-
lity. Nitric oxide can activate guanylate cyclase, the 
enzyme that produces cGMP. The accumulation of 
intracellular cGMP triggers a cascade, leading to de-
creased intracellular calcium level and subsequent 
relaxation of smooth muscle cells (SMCs). And the 
amount of cGMP results from the balance between 
production (NO) and degradation made by phos-
phodiesterase are enzymes that can hydrolyze and 
inactivate cyclic nucleotides. It is known that NO is 
involved in relaxation of the detrusor, bladder neck, 
urethra and prostate (6,12).
 Clinical trials consistently demonstrated 
that PDE5i significantly improve IPSS, most studies 
failed to observe significant improvement in uroflo-
wmetry parameters (13-15). A randomized, double-
-blind and placebo controlled clinical trial showed 
that tadalafil, a phosphodiesterase type 5 inhibitor, 
when administrated in association with tamsulosin 
improves significantly more the storage symptoms 
compared with isolated use of alfa-blocker (16). In 
consequence, the reduction demonstrated in the 
number per minute of micturition cycles after acute 
infusion of sildenafil in NO-deficient rats reinforces 
the hypothesis that PDE5 inhibitors may exert their 
effects probably via bladder.
 This study has some limitations. It has been 
previously known that L-NAME is a non specific 
NOS inhibitor that when administered systemically 
could affect various levels of neuronal or endo-
thelia. In consequence, it has the potential to alter 
physiology of lower urinary tract throughout these 
mechanisms. Additionally, we did not evaluate the 
pharmacological effects on molecular or morpholo-
gical grounds of lower urinary tract.
cONclUSIONS
Systemic reduction of nitric oxide causes 
detrusor overactivity and acute infusion of silde-
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